bpc 157 contraindications BPC-157: Miracle Healing Peptide or Hidden Danger? BPC-157 Peptide Therapy | Regenerative

B., Tvrdeic, A., Pavlov, K

The specific compounds now under PCAC review carry decades of independent research behind them: GHK-Cu was first characterised in a 1980 Nature paper by Loren Pickart as a copper-binding plasma tripeptide

nanomolar in cell culture Important: These are experimental doses used in animal studies and cannot be extrapolated to other species due to significant differences in metabolism, receptor density, pharmacokinetics, peptide degradation rates, and PepT1 expression patterns

This means BPC-157's primary superpower is angiogenesis the rapid creation of new blood vessels

This research has been particularly interesting in models where animals were rendered dopamine-depleted or exposed to neurotoxic substances BPC-157 appeared to exert protective and partially restorative effects in these conditions